158 related articles for article (PubMed ID: 15070703)
21. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
22. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
Nagata T; Werner MH
J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
[TBL] [Abstract][Full Text] [Related]
23. The chimeric protein, PEBP2 beta/CBF beta-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation.
Tanaka Y; Fujii M; Hayashi K; Chiba N; Akaishi T; Shineha R; Nishihira T; Satomi S; Ito Y; Watanabe T; Satake M
Oncogene; 1998 Aug; 17(6):699-708. PubMed ID: 9715271
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of core-binding factor alpha (CBF alpha) reverses cellular transformation by the CBF beta-smooth muscle myosin heavy chain chimeric oncoprotein.
Hajra A; Liu PP; Speck NA; Collins FS
Mol Cell Biol; 1995 Sep; 15(9):4980-9. PubMed ID: 7651416
[TBL] [Abstract][Full Text] [Related]
25. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
Ohki M
Semin Cancer Biol; 1993 Dec; 4(6):369-75. PubMed ID: 8142622
[TBL] [Abstract][Full Text] [Related]
27. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation.
Cao W; Adya N; Britos-Bray M; Liu PP; Friedman AD
J Biol Chem; 1998 Nov; 273(47):31534-40. PubMed ID: 9813068
[TBL] [Abstract][Full Text] [Related]
28. AML1 stimulates G1 to S progression via its transactivation domain.
Bernardin F; Friedman AD
Oncogene; 2002 May; 21(20):3247-52. PubMed ID: 12082641
[TBL] [Abstract][Full Text] [Related]
29. Role of AML1/Runx1 in the pathogenesis of hematological malignancies.
Kurokawa M; Hirai H
Cancer Sci; 2003 Oct; 94(10):841-6. PubMed ID: 14556655
[TBL] [Abstract][Full Text] [Related]
30. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
31. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
Hyde RK; Zhao L; Alemu L; Liu PP
Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
[TBL] [Abstract][Full Text] [Related]
32. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
33. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.
Pulikkan JA; Hegde M; Ahmad HM; Belaghzal H; Illendula A; Yu J; O'Hagan K; Ou J; Muller-Tidow C; Wolfe SA; Zhu LJ; Dekker J; Bushweller JH; Castilla LH
Cell; 2018 Jun; 174(1):172-186.e21. PubMed ID: 29958106
[TBL] [Abstract][Full Text] [Related]
34. Crystallization and preliminary studies of the DNA-binding runt domain of AML1.
Bäckström S; Huang SH; Wolf-Watz M; Xie XQ; Härd T; Grundström T; Sauer UH
Acta Crystallogr D Biol Crystallogr; 2001 Feb; 57(Pt 2):269-71. PubMed ID: 11173476
[TBL] [Abstract][Full Text] [Related]
35. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
36. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
37. Multiple regions of ETO cooperate in transcriptional repression.
Hildebrand D; Tiefenbach J; Heinzel T; Grez M; Maurer AB
J Biol Chem; 2001 Mar; 276(13):9889-95. PubMed ID: 11150306
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.
Shigesada K; van de Sluis B; Liu PP
Oncogene; 2004 May; 23(24):4297-307. PubMed ID: 15156186
[TBL] [Abstract][Full Text] [Related]
39. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
40. Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).
Gu TL; Goetz TL; Graves BJ; Speck NA
Mol Cell Biol; 2000 Jan; 20(1):91-103. PubMed ID: 10594012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
